文献速递糖尿病

免疫检查点抑制剂与1型糖尿病风险

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2022-01-01

该研究利用Optum Clinformatics Data Mart数据库,评估2017至2020年间接受免疫检查点抑制剂(ICI)治疗患者中1型糖尿病(T1DM)的发生率与特征。在30,337例患者中,ICI相关T1DM发生率为0.86%(261例)。双免疫联合治疗、较年轻年龄及既存非T1DM糖尿病与风险升高相关,而既往免疫抑制剂使用与风险降低相关。ICI-T1DM似乎未显著影响患者生存。

要点

  • ICI-T1DM在30,337例接受ICI治疗患者中发生率为0.86%(261例)。
  • CTLA-4与PD-1/PD-L1双抗体联合使用较单用PD-1/PD-L1抗体与ICI-T1DM风险升高相关(HR 1.62;95%CI 1.15-2.26)。
  • 较年轻年龄(每年轻5岁HR 1.19;95%CI 1.13-1.25)和既存非T1DM糖尿病(HR 4.48;95%CI 3.45-5.83)与ICI-T1DM风险升高相关。

核心结论

  • ICI-T1DM风险与ICI治疗类型、患者年龄及既存非T1DM糖尿病相关,这些数据可能有助于指导ICI治疗期间的风险评估和筛查实践。

研究设计与样本

  • 研究使用Optum的Clinformatics Data Mart数据库,对2017至2020年间接受ICI治疗的大型去标识化患者队列中T1DM的发生率和特征进行评估。
  • 应用Fine-Gray和病因特异性风险模型研究患者/治疗特征与ICI-T1DM的关联,并应用以ICI-T1DM为时间变化协变量的Cox模型评估ICI-T1DM对生存的影响。

主要发现

  • 在30,337例接受ICI治疗的患者中,观察到261例(0.86%)发生ICI-T1DM。
  • 与单用抗PD-L1或抗PD-1抗体相比,CTLA-4与PD-1或PD-L1双抗体联合使用与ICI-T1DM风险升高相关(HR 1.62;95%CI 1.15-2.26)。
  • 较年轻年龄(每年轻5岁HR 1.19;95%CI 1.13-1.25)和既存非T1DM糖尿病(HR 4.48;95%CI 3.45-5.83)也与ICI-T1DM风险升高相关。
  • 相反,既往使用免疫抑制药物与ICI-T1DM发生率降低相关(HR 0.57;95%CI 0.34-0.95),但其保护作用部分可能归因于死亡率增加。
  • ICI-T1DM的发生似乎未显著影响患者生存。

临床怎么用

  • 原文结论指出,这些数据可能有助于指导ICI治疗期间患者的风险评估和筛查实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 1 diabetes mellitus (T1DM) is a rare, irreversible immune-related adverse event reported in patients receiving treatment with immune checkpoint inhibitors (ICI). However, clinical risk factors for ICI-induced T1DM (ICI-T1DM) and its impact on survival in patients remain unknown. RESEARCH DESIGN AND METHODS: We used Optum's Clinformatics Data Mart database for assessment of the incidence and characteristics of T1DM in a large de-identified cohort of patients treated with ICI between 2017 and 2020. We applied Fine-Gray and cause-specific hazard models to study associations between patient/treatment characteristics and ICI-T1DM and applied the Cox model with ICI-T1DM as a time-varying covariate to assess the impact of ICI-T1DM on survival. RESULTS: ICI-T1DM was observed in 261 of 30,337 (0.86%) patients. Dual use of antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) was associated with increasing risk of ICI-T1DM (hazard ratio [HR] 1.62; 95% CI 1.15-2.26) vs. anti-PD-L1 or anti-PD-1 alone. Younger age (HR 1.19 for every 5-year decrease; 95% CI 1.13-1.25) and preexisting non-T1DM diabetes (HR 4.48; 95% CI 3.45-5.83) were also associated with higher risk of ICI-T1DM. Conversely, prior use of immunosuppressive medications (HR 0.57; 95% CI 0.34-0.95) was associated with lower incidence of ICI-T1DM, but part of its protective effect may be due to the increased mortality rate. Development of ICI-T1DM does not seem to significantly impact patient survival. CONCLUSIONS: The risk of ICI-T1DM is associated with the type of ICI therapy, patient age, and preexisting non-T1DM diabetes. These data may help guide risk assessment and screening practices for patients during ICI therapy.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Chen X, Affinati AH, Lee Y, et al. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. Diabetes Care. 2022. PMID: 35238899. doi:10.2337/dc21-2213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。